FDA Clears New CAR-T Therapy for Multiple MyelomaMarch 2nd 2022
FDA approved Legend Biotech’s chimeric antigen receptor T-cell (CAR-T) treatment, Carvykti (ciltacabtagene autoleucel; cilta- cel), to treat relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy.
Employers Face Barriers With Adopting BiosimilarsMarch 1st 2022
Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
Researchers: Ancillary Services Would Comprise 20% of Medicare Spending on AduhelmJanuary 15th 2022
In a research letter published in JAMA Health Forum, researchers say most of the cost figures for Aduhelm have left out the additional MRI scans and other services that will be required because the drug is associated with the development of amyloid-related imaging abnormalities (ARIAs).
Analyst Report: These 7 Treatments Destined To Be Blockbusters Within 5 YearsJanuary 10th 2022
Lecanemab and donanemab, monoclonal antibodies for Alzheimer’s, are on the list of drugs in late-stage development that Clarivate analysts will have annual sales of a $1 billion or more in the next five years.